Study guide

10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies

Philippine Medical Technologists Licensure Examination MTLE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Clinical Chemistry: Laboratory Operations, Instrumentation, Reagents, Quality Assurance, and Safety

1.1 Specimen Collection, Preanalytical Variables, and Interferences 1.2 Clinical Chemistry Instrumentation, Photometry, and Automation 1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics 1.4 Reagent Preparation, Laboratory Water, Glassware, Pipettes, and Centrifuges 1.5 Laboratory Safety: Chemical, Fire, Electrical, Biological, and Physical Hazards

2 Chapter 2: Clinical Chemistry: Carbohydrates, Lipids, Proteins, Non-Protein Nitrogen, and Liver Function

2.1 Glucose Homeostasis, Diagnostic Criteria for Diabetes Mellitus, and Glycemic Monitoring 2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment 2.3 Serum Proteins, Albumin, Globulins, and Serum Protein Electrophoresis Patterns 2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function 2.5 Liver Function Tests, Bilirubin Metabolism, and Jaundice

3 Chapter 3: Clinical Chemistry: Electrolytes, Blood Gases, Enzymology, Endocrinology, and Toxicology

3.1 Water Balance, Electrolytes, Osmolality, and Anion Gap Calculations 3.2 Blood Gas Analysis, Oxygenation, and Acid-Base Homeostasis 3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes 3.4 Endocrinology: Hormone Physiology and Endocrine Function Testing 3.5 Therapeutic Drug Monitoring and Clinical Toxicology

4 Chapter 4: Bacteriology: Specimen Management, Media, Staining, and Biosafety

4.1 Specimen Collection, Transport, Processing, and Microscopic Staining 4.2 Culture Media Classification, Quality Control, and Inoculation Techniques 4.3 Sterilization, Disinfection, Decontamination, and Biosafety Containment 4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms

5 Chapter 5: Diagnostic Bacteriology: Major Pathogenic Bacteria

5.1 Medically Important Gram-Positive Cocci: Staphylococci, Streptococci, and Enterococci 5.2 Medically Important Gram-Negative Bacilli: Enterobacterales and Non-Fermenters 5.3 Fastidious, Microaerophilic, and Anaerobic Bacteria 5.4 Mycobacteria, Spirochetes, Atypical Bacteria, and Public Health Microbiology

6 Chapter 6: Medical Parasitology, Mycology, and Diagnostic Virology

6.1 Stool Examination Techniques and Intestinal Nematodes 6.2 Tissue Nematodes, Filarial Worms, Cestodes, and Trematodes 6.3 Medical Protozoology: Intestinal, Urogenital, and Blood/Tissue Protozoa 6.4 Medical Mycology: Yeasts, Dermatophytes, Dimorphic Fungi, and Opportunistic Molds 6.5 Clinical Virology: Viral Structure, Specimen Handling, and Diagnostic Methods

7 Chapter 7: Hematology: Specimen Collection, Routine Parameters, Instrumentation, and Manual Methods

7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality 7.2 Automated Cell Counting Principles, Complete Blood Count Parameters, and Erythrocyte Indices 7.3 Reticulocyte Evaluation, Supravital Staining, and Erythrocyte Sedimentation Rate 7.4 Manual Cell Counts, Manual Hemoglobin Methods, and Hematology Quality Control

8 Chapter 8: Hematology: Blood Cell Morphology, Bone Marrow, and Hematologic Disorders

8.1 Normal Erythropoiesis and Erythrocyte Morphologic Abnormalities 8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies 8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations 8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders 8.5 Peripheral Blood Smear Preparation and Staining, Bone Marrow Examination, and Cytochemistry

9 Chapter 9: Hemostasis: Coagulation and Platelet Function Testing and Hemostatic Disorders

9.1 Mechanisms of Primary and Secondary Hemostasis, Fibrinolysis, and Natural Inhibitors 9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies 9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias 9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests

10 Chapter 10: Immunohematology: Blood Group Systems and Antiglobulin Testing

10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies 10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems 10.3 Antiglobulin Testing, Elution, Adsorption, and Special Antibody Procedures

11 Chapter 11: Blood Banking: Donor Operations, Component Therapy, and Adverse Reactions

11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing 11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion 11.3 Pre-Transfusion Compatibility Testing and Transfusion Reactions 11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin

12 Chapter 12: Clinical Serology and Immunology

12.1 Principles of Immunology: Antigens, Antibodies, Complement, and Immune Responses 12.2 Serologic Testing Methodologies: Agglutination, Precipitation, Flocculation, and Labeled Immunoassays 12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins 12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)

13 Chapter 13: Clinical Microscopy: Urinalysis and Renal Pathology

13.1 Renal Physiology, Urine Formation, and Physical Examination of Urine 13.2 Chemical Examination of Urine: Reagent Strip Principles, Interferences, and Confirmatory Tests 13.3 Microscopic Examination of Urine Sediment: Cells, Casts, Crystals, and Contaminants 13.4 Renal Calculi, Glomerular/Tubular/Interstitial Renal Diseases, and Urinalysis Quality Control

14 Chapter 14: Clinical Microscopy: Body Fluids, Fecal Analysis, and Gastric, Duodenal, and Respiratory Specimens

14.1 Cerebrospinal Fluid Analysis: Collection, Cell Counts, Chemistry, and Microbiology 14.2 Serous Fluids (Pleural, Pericardial, Peritoneal: Transudates vs Exudates) and Synovial Fluid Analysis 14.3 Seminal Fluid and Amniotic Fluid Analysis 14.4 Fecal Analysis: Macroscopic, Microscopic, and Chemical Examination of Stool 14.5 Gastric Fluid, Duodenal Contents, Sputum, and Bronchoalveolar Specimens

15 Chapter 15: Histopathologic Techniques and Cytotechnology

15.1 Tissue Preservation, Fixation, Decalcification, and Processing Steps 15.2 Microtomy, Sectioning Artifacts, Hematoxylin and Eosin Staining, and Special Stains 15.3 Cytotechnology: Specimen Collection, Fixation, Papanicolaou Staining, and the Bethesda System 15.4 Special Procedures: Frozen Sections, Special Embedding, Immunohistochemistry, Electron Microscopy, Autopsy, Museum Techniques, and Laboratory Records

16 Chapter 16: Medical Technology Laws, Related Laws, and Ethics

16.1 Republic Act No. 5527 (The Philippine Medical Technology Act of 1969) and Key Amendments 16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics

10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies

Key Takeaways Explain This Topic AI

Landsteiner's rule dictates that immunocompetent individuals predictably possess reciprocal, naturally occurring isohemagglutinins in their serum against ABO antigens absent from their red blood cells; these antibodies are predominantly IgM (with prominent IgG in group O) and readily activate classical complement to cause fatal acute intravascular hemolysis.

Biosynthesis of ABH antigens requires sequential glycosyltransferases: the FUT1 (H) gene encodes alpha-1,2-fucosyltransferase adding L-fucose to Type 2 precursor chains to form H substance, while A and B genes encode alpha-1,3-N-acetylgalactosaminyltransferase and alpha-1,3-D-galactosyltransferase, respectively; the O gene is an amorph, leaving H substance unmodified in the quantitative hierarchy O > A2 > B > A2B > A1 > A1B.

The Bombay phenotype (Oh, hh genotype) results from homozygous inheritance of silent h alleles, completely lacking H, A, and B antigens on erythrocytes; their serum contains potent, wide-thermal-range anti-A, anti-B, and anti-H that violently lyses all normal group O red cells, rendering them compatible strictly with other Bombay donors.

ABO subgroups A1 and A2 exhibit both quantitative site density differences and qualitative structural variations; Dolichos biflorus lectin agglutinates A1 but not A2 cells, and 1-8% of A2 and 22-35% of A2B individuals produce anti-A1 alloantibodies that trigger unexpected reverse grouping discrepancies.

ABO discrepancies are categorized into four systematic classes: Group I (weak or missing reverse antibodies), Group II (weak or missing forward antigens, including acquired B), Group III (plasma protein rouleaux, resolved by saline replacement), and Group IV (cold autoantibodies, cold alloantibodies, or Wharton's jelly, resolved by 37°C prewarming, adsorption, or extended washing).

Last updated: October 2026

The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies

The ABO blood group system, discovered by Karl Landsteiner in 1900–1901, represents the most critical antigenic system in transfusion medicine and clinical immunohematology. Unlike all other human blood group systems, ABO is the only system in which individuals predictably and consistently produce reciprocal antibodies in their plasma against the erythrocyte antigens they lack. Because anti-A and anti-B antibodies are potent complement activators capable of triggering catastrophic, life-threatening acute intravascular hemolytic transfusion reactions within minutes of incompatible red cell infusion, absolute concordance between forward (cell) and reverse (serum) grouping is an inviolable requirement before any blood component is released for transfusion.

1. Landsteiner's Rule and Physiological Principles

Landsteiner's rule is the foundational law of immunohematology: an individual predictably and naturally produces antibodies in their serum or plasma directed against the ABO antigens absent from their own erythrocyte membranes , provided they possess an intact, immunocompetent immune system. ┌─────────────────────────────────────────────────────────┐

  • │ Landsteiner's Reciprocal Rule │
  • └────────────────────────────┬────────────────────────────┘
  • │
  • ┌────────────────────────────┬───────────────┴────────────┬───────────────────────────┐
  • ▼ ▼ ▼ ▼
  • ┌──────────────┐ ┌──────────────┐ ┌──────────────┐ ┌──────────────┐
  • │ Group O │ │ Group A │ │ Group B │ │ Group AB │
  • └──────┬───────┘ └──────┬───────┘ └──────┬───────┘ └──────┬───────┘
  • │ │ │ │
  • Antigens: H only • Antigens: A, H • Antigens: B, H • Antigens: A, B, H
  • Antibodies: • Antibodies: • Antibodies: • Antibodies:
  • Anti-A, Anti-B, Anti-B Anti-A None
  • Anti-A,B (IgG + IgM) (predominantly IgM) (predominantly IgM) • Universal Recipient
  • Universal RBC Donor • Compatible RBCs: • Compatible RBCs: (for RBCs)
  • Universal Plasma Recip. A, O B, O • Universal Plasma Donor
  • Antibody Characteristics and Immunoglobulin Isotypes

Isohemagglutinins (Naturally Occurring Antibodies) : Production of anti-A and anti-B antibodies begins around 3 to 6 months of age, triggered by environmental exposure to ubiquitous bacterial, viral, and dietary oligosaccharides structurally identical to human ABH antigens (such as cell wall lipopolysaccharides of Escherichia coli ). Antibody titers peak between 5 and 10 years of age and gradually decline in advanced senescence.

Immunoglobulin Classes :

Group A and Group B Individuals : Their serum isohemagglutinins (anti-B in group A; anti-A in group B) are predominantly high-molecular-weight IgM pentamers, with minor fractions of IgG and IgA. These IgM antibodies react strongly at room temperature ( 20 – 24 ∘ C 20\text{--}24^\circ\text{C} 20 – 2 4 ∘ C ) and below, but remain active at 37 ∘ C 37^\circ\text{C} 3 7 ∘ C .

Group O Individuals : Their serum contains anti-A, anti-B, and a cross-reacting antibody designated anti-A,B . These antibodies are predominantly IgG (specifically subclasses I g G 1 IgG_1 I g G 1 ​ and I g G 3 IgG_3 I g G 3 ​ ), accompanied by IgM. Because monomeric IgG readily crosses the placental syncytiotrophoblast barrier via neonatal Fc receptors ( F c R n FcRn F c R n ), maternal group O women carrying group A or group B fetuses are uniquely predisposed to delivering neonates with ABO Hemolytic Disease of the Fetus and Newborn (ABO HDFN).

Complement Activation and Intravascular Hemolysis : IgM isohemagglutinins possess a planar pentameric geometry with 10 antigen-binding Fab fragments. A single bound IgM molecule on an erythrocyte membrane can change into a "staple" conformation, exposing its C H 3 C_H3 C H ​ 3 domains and binding the C 1 q C1q C 1 q subunit of the classical complement cascade. Complement activation rapidly proceeds through the terminal membrane attack complex ( C 5 b - 9 C5b\text{-}9 C 5 b - 9 ), punching lytic pores into the erythrocyte membrane and triggering massive, immediate acute intravascular hemolysis , accompanied by free hemoglobinemia, hemoglobinuria, disseminated intravascular coagulation (DIC), and acute renal failure.

2. Biochemical Genetics of ABH Antigens and Transferases

ABH blood group antigens are not direct gene products; instead, genes encode specific glycosyltransferase enzymes that catalyze the sequential addition of immunodominant carbohydrate residues to pre-existing carbohydrate precursor chains. ┌──────────────────────────────────────────────┐

  • │ ABH Biosynthetic Pathway │
  • └──────────────────────┬───────────────────────┘
  • │
  • ▼
  • Type 2 Precursor Oligosaccharide
  • [Gal-beta-1,4-GlcNAc-R]
  • │
  • │ FUT1 Gene (Chromosome 19)
  • │ alpha-1,2-fucosyltransferase
  • │ (+ L-Fucose)
  • ▼
  • H Antigen
  • [Fuc-alpha-1,2-Gal-beta-1,4-GlcNAc-R]
  • │
  • ┌────────────────────────┴────────────────────────┐
  • │ │
  • ▼ ▼
  • A Gene (Chromosome 9) B Gene (Chromosome 9)
  • alpha-1,3-N-acetylgalactosaminyltransferase alpha-1,3-D-galactosyltransferase
  • (+ GalNAc) (+ D-Galactose)
  • ▼ ▼
  • A Antigen B Antigen
  • [GalNAc-alpha-1,3-(Fuc-alpha-1,2)-Gal...] [Gal-alpha-1,3-(Fuc-alpha-1,2)-Gal...]
  • The Precursor Substance and the H Gene ( FUT1 )

Precursor Chains : Oligosaccharide chains terminate with β \beta β -D-galactose attached to subterminal N-acetylglucosamine. In Type 1 precursor chains (found primarily in secretory fluids and endodermally derived epithelial tissues), the terminal galactose is linked by a β - 1 , 3 \beta\text{-}1,3 β - 1 , 3 glycosidic bond to N-acetylglucosamine. In Type 2 precursor chains (found primarily on erythrocyte membranes and glycolipids/glycoproteins of mesodermal and ectodermal origin), the terminal galactose is linked by a β - 1 , 4 \beta\text{-}1,4 β - 1 , 4 glycosidic bond.

The H Locus ( FUT1 ) : Located on chromosome 19 q 13.3 19q13.3 19 q 13.3 , the H H H gene encodes α \alpha α -1,2-L-fucosyltransferase . This enzyme transfers an immunodominant sugar, L-fucose , from guanosine diphosphate L-fucose (GDP-Fuc) to the terminal D-galactose of Type 2 chains via an α - 1 , 2 \alpha\text{-}1,2 α - 1 , 2 linkage, producing the H antigen (H substance).

Obligate Precursor Role : The H antigen is the mandatory substrate required by both the A and B transferases. Without H antigen synthesis, neither the A nor B transferase can attach its respective immunodominant sugar.

The ABO Locus and Immunodominant Sugars

The ABO locus, mapped to chromosome 9 q 34.2 9q34.2 9 q 34.2 , comprises seven exons and exhibits multiple functional alleles:

The A Gene : Encodes α \alpha α -1,3-N-acetylgalactosaminyltransferase , which transfers N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the terminal D-galactose of H substance via an α - 1 , 3 \alpha\text{-}1,3 α - 1 , 3 linkage, generating the A antigen .

The B Gene : Differs from the A 1 A^1 A 1 allele by only seven nucleotide substitutions, four of which cause critical amino acid changes ( A r g 176 G l y Arg176Gly A r g 176 Gl y , G l y 235 S e r Gly235Ser Gl y 235 S er , L e u 266 M e t Leu266Met L e u 266 M e t , and G l y 268 A l a Gly268Ala Gl y 268 A l a ) that alter the transferase donor-substrate specificity. The B gene encodes α \alpha α -1,3-D-galactosyltransferase , which transfers D-galactose from UDP-Gal to the terminal galactose of H substance via an α - 1 , 3 \alpha\text{-}1,3 α - 1 , 3 linkage, generating the B antigen .

The O Gene (Amorph) : Contains a single critical base deletion of guanine at nucleotide position 261 ( Δ 261 \Delta 261 Δ261 ) within exon 6. This deletion induces a reading frameshift that introduces a premature translation termination codon, producing an enzymatically truncated, non-functional protein. Consequently, homozygous O O OO OO individuals cannot modify H substance; their erythrocytes express abundant, unmodified H antigen.

Quantitative Hierarchy of Unmodified H Antigen Sites

Because the A and B transferases compete for and consume pre-existing H antigen sites with varying catalytic efficiencies, the density of remaining unmodified H substance on normal human red blood cells follows a strict descending hierarchy: O > A 2 > B > A 2 B > A 1 > A 1 B \mathbf{O > A_2 > B > A_2B > A_1 > A_1B} O > A 2 ​ > B > A 2 ​ B > A 1 ​ > A 1 ​ B

Clinical Testing : The plant seed lectin extracted from Ulex europaeus serves as commercial anti-H reagent. It agglutinates group O cells with the highest intensity ( 4 + 4+ 4 + ) and reacts weakly or negatively with group A 1 A_1 A 1 ​ and A 1 B A_1B A 1 ​ B cells ( 0 to 1 + 0\text{ to }1+ 0 to 1 + ), confirming that A 1 A_1 A 1 ​ transferases consume nearly all available H chains.

3. The Bombay Phenotype ( O h O_h O h ​ , h h hh hh ) and Secretor Genetics ┌─────────────────────────────────────────────────────────┐

  • │ Bombay Phenotype (Oh / hh Genotype) │
  • └────────────────────────────┬────────────────────────────┘
  • │
  • ┌─────────────────────────────────────┴─────────────────────────────────────┐
  • ▼ ▼
  • Forward Cell Grouping Reverse Serum Grouping
  • Anti-A: 0 (Negative) • A1 Reagent Cells: 4+ Lysis/Agglutination
  • Anti-B: 0 (Negative) • B Reagent Cells: 4+ Lysis/Agglutination
  • Anti-A,B: 0 (Negative) • O Reagent Cells: 4+ Lysis/Agglutination
  • Anti-H Lectin (Ulex): 0 (Negative!) • Potent, wide thermal range Anti-H
  • [Mistaken for normal Group O on routine screen] (4°C to 37°C; violently hemolyzes O cells)
  • The Bombay Phenotype ( O h O_h O h ​ )

Discovered in 1952 by Bhende and colleagues in Bombay (now Mumbai), India, the classic Bombay phenotype is inherited as a rare autosomal recessive trait with an approximate frequency of 1 in 10,000 in India and 1 in 1,000,000 in Western populations:

Genetics : Caused by homozygous inheritance of the silent, non-functional h h h allele ( FUT1 null, genotype h h hh hh ). Bombay individuals completely lack α \alpha α -1,2-fucosyltransferase activity and cannot synthesize H antigen on erythrocyte Type 2 chains. Even if they possess normal A A A or B B B genes on chromosome 9, the A and B transferases remain inactive because their obligate acceptor substrate (H substance) is entirely absent.

Serologic Profile :

Forward Grouping : Anti-A: 0 0 0 ; Anti-B: 0 0 0 ; Anti-A,B: 0 0 0 . The cells appear to be standard Group O.

Lectins : Completely negative with Ulex europaeus anti-H lectin ( 0 0 0 ). Normal group O cells react at 4 + 4+ 4 + .

Reverse Grouping : Serum strongly agglutinates A 1 A_1 A 1 ​ cells ( 4 + 4+ 4 + ), B cells ( 4 + 4+ 4 + ), and all normal group O screening cells ( 4 + 4+ 4 + ) at room temperature and 37 ∘ C 37^\circ\text{C} 3 7 ∘ C .

The Bombay Anti-H : Normal group O individuals lack anti-H because their cells are saturated with H antigen. In contrast, Bombay ( h h hh hh ) individuals produce a potent, naturally occurring allo-anti-H. This alloantibody exhibits a wide thermal amplitude (reactive from 4 ∘ C 4^\circ\text{C} 4 ∘ C to 37 ∘ C 37^\circ\text{C} 3 7 ∘ C ), readily binds complement, and induces violent intravascular hemolysis of any transfused normal group O blood.

Transfusion Management : Bombay individuals can receive red blood cells ONLY from other documented Bombay ( O h O_h O h ​ ) donors . Transfusing standard group O red cells is rapidly fatal. Family pedigree screening, autologous blood pre-donation, and national/international rare donor registries are vital.

Secretor Status and the FUT2 Gene

Soluble ABH blood group substances present in body fluids (saliva, tears, gastric juice, bile, milk, and semen) are controlled by the independent S e Se S e locus ( FUT2 ) on chromosome 19 q 13.3 19q13.3 19 q 13.3 :

Function : The S e Se S e gene encodes α \alpha α -1,2-L-fucosyltransferase-2, which operates specifically on Type 1 precursor chains in secretory epithelial cells. Individuals who inherit at least one functional S e Se S e allele ( S e S e SeSe S e S e or S e s e Sese S ese , representing approximately 80% of the population ) are designated Secretors . Individuals homozygous for the inactive s e se se allele ( s e s e sese sese , approximately 20% of the population ) are Non-Secretors .

Antigen Expression in Secretions :

  • ABO Genotype Secretor Status Soluble Substances Present in Saliva
  • A / A or A / O Secretor ( Se_ ) A and H substances
  • B / B or B / O Secretor ( Se_ ) B and H substances
  • A / B Secretor ( Se_ ) A, B, and H substances
  • O / O Secretor ( Se_ ) H substance only
  • Any ABO type Non-Secretor ( sese ) No A, B, or H substances
  • Bombay ( h h hh hh ) Non-Secretor ( sese ) No A, B, or H substances

Saliva Neutralization / Inhibition Assay : To confirm secretor status, boiled saliva (which inactivates endogenous carbohydrate-cleaving enzymes) is incubated with standardized dilutions of commercial anti-A, anti-B, or anti-H. Reagent indicator red cells are subsequently added. If soluble antigens are present in the saliva, they neutralize the antiserum, resulting in inhibition of agglutination (negative reaction indicates secretor) . If no soluble antigens are present, free antiserum agglutinates the indicator cells ( agglutination indicates non-secretor ).

4. ABO Subgroups: A 1 A_1 A 1 ​ vs A 2 A_2 A 2 ​ and Weak Subgroups

Subgroups of group A represent inherited phenotypic variations in the quantity and structural complexity of A antigens expressed on erythrocyte membranes. The two principal subgroups are A 1 A_1 A 1 ​ (accounting for approximately 80% of all group A individuals) and A 2 A_2 A 2 ​ (accounting for the remaining 20% ). ┌──────────────────────────────────────────────┐

  • │ Differentiating A1 and A2 Phenotypes │
  • └──────────────────────┬───────────────────────┘
  • │
  • ┌────────────────────────────────┴────────────────────────────────┐
  • ▼ ▼
  • A1 Subgroup (80%) A2 Subgroup (20%)
  • Antigen Sites: 810,000 to 1,170,000 / RBC • Antigen Sites: 240,000 to 290,000 / RBC
  • Transferase: High catalytic efficiency • Transferase: Lower pH optimum, slower kinetics
  • Dolichos biflorus (Anti-A1 lectin): 4+ • Dolichos biflorus (Anti-A1 lectin): 0 (Negative)
  • Anti-H Lectin (Ulex): 0 to 1+ (Weak) • Anti-H Lectin (Ulex): 3+ to 4+ (Strong)
  • Anti-A1 Alloantibody: Never produced • Anti-A1 Alloantibody: Produced by 1% to 8% of A2
  • and 22% to 35% of A2B individuals
  • Quantitative and Qualitative Distinctions

Quantitative : A 1 A_1 A 1 ​ red blood cells express between 810 , 000 810,000 810 , 000 and 1 , 170 , 000 1,170,000 1 , 170 , 000 A antigen sites per erythrocyte, whereas A 2 A_2 A 2 ​ red blood cells express only 240 , 000 240,000 240 , 000 to 290 , 000 290,000 290 , 000 sites per erythrocyte (an approximate four-fold reduction).

Qualitative : The A 1 A^1 A 1 transferase operates over a broad pH range and efficiently modifies both linear and complex branched carbohydrate chains into A antigens. The A 2 A^2 A 2 transferase possesses a restricted, lower pH optimum and cannot efficiently glycosylate complex branched H structures, leaving substantial unmodified H antigen on the cell membrane.

Reagent Lectins for Differentiation :

Dolichos biflorus (Anti- A 1 A_1 A 1 ​ Lectin) : Prepared from the seeds of the horse gram plant. When diluted appropriately, it specifically agglutinates A 1 A_1 A 1 ​ and A 1 B A_1B A 1 ​ B erythrocytes ( 3 + to 4 + 3+\text{ to }4+ 3 + to 4 + ), but does NOT agglutinate A 2 A_2 A 2 ​ or A 2 B A_2B A 2 ​ B erythrocytes ( 0 0 0 ).

Ulex europaeus (Anti-H Lectin) : Agglutinates A 2 A_2 A 2 ​ cells strongly ( 3 + to 4 + 3+\text{ to }4+ 3 + to 4 + ) because of high residual H antigen density, but reacts weakly or negatively with A 1 A_1 A 1 ​ cells ( 0 to 1 + 0\text{ to }1+ 0 to 1 + ).

The Anti- A 1 A_1 A 1 ​ Alloantibody :

Approximately 1% to 8% of A 2 A_2 A 2 ​ individuals and 22% to 35% of A 2 B A_2B A 2 ​ B individuals produce an unexpected allo-anti- A 1 A_1 A 1 ​ in their serum.

Serologic Impact : When testing an A 2 A_2 A 2 ​ or A 2 B A_2B A 2 ​ B patient, forward typing indicates group A or AB, but reverse typing with reagent A 1 A_1 A 1 ​ cells displays an unexpected 1 + to 2 + 1+\text{ to }2+ 1 + to 2 + agglutination reaction, creating an apparent ABO discrepancy.

Clinical Significance : Anti- A 1 A_1 A 1 ​ is typically a benign, cold-reactive IgM antibody active only at room temperature ( 20 – 24 ∘ C 20\text{--}24^\circ\text{C} 20 – 2 4 ∘ C ) or below, making it clinically insignificant. However, if the antibody remains active at 37 ∘ C 37^\circ\text{C} 3 7 ∘ C and reacts in the indirect antiglobulin test (IAT), it is clinically significant and capable of causing shortened erythrocyte survival; such patients must receive A 2 A_2 A 2 ​ or group O red cells.

Rare Weak Subgroups of Group A

A 3 A_3 A 3 ​ : Characterized by a pathognomonic mixed-field agglutination pattern with commercial anti-A and anti-A,B reagents (small agglutinated clumps interspersed within a predominant field of unagglutinated free red blood cells). Saliva of A 3 A_3 A 3 ​ secretors contains A and H substances.

A x A_x A x ​ : Typically yields negative or barely perceptible reactions with anti-A, but agglutinates ( 1 + to 2 + 1+\text{ to }2+ 1 + to 2 + ) with polyclonal anti-A,B reagent. Their serum almost always contains clinically significant anti- A 1 A_1 A 1 ​ . Saliva contains only H substance (no A substance).

A e n d A_{end} A e n d ​ : Displays very weak, mixed-field agglutination with anti-A (<10% of cells agglutinate). Secretions contain only H substance.

A e l A_{el} A e l ​ : Fails to agglutinate with anti-A or anti-A,B reagents. Presence of A antigen is demonstrable solely through adsorption and heat/acid elution techniques.

5. Forward and Reverse Typing and ABO Discrepancies

Routine ABO grouping consists of two independent tests that must show reciprocal agreement:

Forward (Front / Cell) Grouping : Tests patient red blood cells with commercial monoclonal antisera ( Anti-A , Anti-B , and optionally Anti-A,B ) to identify erythrocyte surface antigens.

Reverse (Back / Serum) Grouping : Tests patient serum or plasma against known commercial reagent erythrocytes ( A 1 A_1 A 1 ​ cells and B cells ) to identify expected reciprocal isohemagglutinins. ┌─────────────────────────────────────────────────────────┐

  • │ Systematic ABO Discrepancy Resolution │
  • └────────────────────────────┬────────────────────────────┘
  • │
  • ┌──────────────────────────┬───────────────────────┴───────────────────┬──────────────────────────┐
  • ▼ ▼ ▼ ▼
  • ┌──────────────┐ ┌──────────────┐ ┌──────────────┐ ┌──────────────┐
  • │ Group I │ │ Group II │ │ Group III │ │ Group IV │
  • │ Antibodies │ │ Antigens │ │ Proteins │ │ Misc / Cold │
  • └──────┬───────┘ └──────┬───────┘ └──────┬───────┘ └──────┬───────┘
  • │ │ │ │
  • Newborns (<6 mo) • A/B subgroups (A3, Ax) • Multiple Myeloma • Cold auto-anti-I
  • Elderly senescence • Leukemia / MDS • Waldenström's • Cold allo (M, P1, Lea)
  • Hypogammaglobulin. • Acquired B phenomenon • Rouleaux formation • Wharton's jelly
  • Resolution: • Resolution: • Resolution: • Resolution:
  • Incubate 15-30 min Acidified anti-B (pH 6.0), Saline replacement 37°C prewarm, wash
  • at RT or 4°C with anti-A1 lectin, auto-serum technique cord cells, autoadsorb
  • autocontrol control, clinical review
  • Classification, Mechanisms, and Troubleshooting of ABO Discrepancies

An ABO discrepancy occurs whenever the results of forward grouping do not match the expected results of reverse grouping. The technologist must never release blood until the discrepancy is definitively resolved.

Group I Discrepancies (Weak or Missing Reverse Grouping Antibodies)

Pathophysiology : Deficient or undetectable circulating isohemagglutinins in serum.

Common Etiologies :

Newborns under 4 to 6 months of age : Neonates do not synthesize their own isohemagglutinins; any ABO antibodies present are maternal IgG that crossed the placenta. For this reason, reverse typing is not valid or routinely performed on cord blood or neonates.

Elderly patients : Age-related immunosenescence causes progressive decline in antibody titers.

Hypogammaglobulinemia or Agammaglobulinemia : Seen in Bruton's agammaglobulinemia, Severe Combined Immunodeficiency (SCID), Common Variable Immunodeficiency (CVID), and Chronic Lymphocytic Leukemia (CLL).

Immunosuppressed patients : Solid organ transplant or hematopoietic stem cell transplant recipients, chemotherapy patients, or therapeutic plasma exchange recipients.

Chimerism : True genetic chimerism or artificial chimerism post-allogeneic bone marrow transplantation.

Systematic Resolution :

Review patient age, diagnosis, and medication history.

Incubate the serum-cell suspension at room temperature ( 20 – 24 ∘ C 20\text{--}24^\circ\text{C} 20 – 2 4 ∘ C ) for 15 to 30 minutes to enhance cold-reactive IgM binding.

If still negative, incubate the test tubes at 4 ∘ C 4^\circ\text{C} 4 ∘ C for 15 to 30 minutes . Crucial Rule : When incubating at 4 ∘ C 4^\circ\text{C} 4 ∘ C , the technologist MUST concurrently test an Autologous Control (patient cells + patient serum) and a Group O Screening Cell tube . This ensures that positive reactions represent true isohemagglutinins rather than non-specific cold autoantibodies (e.g., auto-anti-I).

Group II Discrepancies (Weak or Missing Forward Grouping Antigens)

Pathophysiology : Weakened, blocked, or altered antigenic expression on the erythrocyte membrane.

Common Etiologies :

Subgroups of A or B : Inheritance of weak alleles ( A 3 , A x , B 3 A_3, A_x, B_3 A 3 ​ , A x ​ , B 3 ​ ).

Hematologic Malignancies : Acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or chronic myelogenous leukemia (CML) can downregulate glycosyltransferase expression, yielding markedly diminished A or B antigen density.

High Concentration of Soluble ABH Substances : In patients with mucin-producing adenocarcinomas (e.g., stomach or ovarian carcinoma), massive quantities of unneutralized soluble A or B substances in unwashed serum neutralize reagent anti-A or anti-B, preventing red cell agglutination.

The Acquired B Phenomenon : Occurs in Group A 1 A_1 A 1 ​ individuals suffering from severe lower gastrointestinal diseases (colorectal adenocarcinoma, intestinal obstruction, bowel perforation, or Escherichia coli / Proteus vulgaris septicemia). Bacterial enzymes ( deacetylases ) cleave the acetyl group from N-acetylgalactosamine (the Group A immunodominant sugar) on the patient's red cells, converting it into D-galactosamine . Structurally, galactosamine cross-reacts with certain monoclonal anti-B reagent clones (particularly clone ES-4), falsely typing the forward cells as Group AB while the reverse typing remains Group A (with intact anti-B in serum).

Systematic Resolution :

Wash patient erythrocytes 3 to 4 times with isotonic saline to remove excess soluble substances.

To resolve Acquired B : Test patient red blood cells with acidified anti-B reagent (adjusted to pH 6.0) . At pH 6.0, anti-B does NOT agglutinate acquired B cells but agglutinates true Group B cells. Concurrently, test the patient's red cells against their own autologous serum : the patient's endogenous anti-B will not agglutinate their own acquired B cells.

Test with anti-A,B reagent and anti- A 1 A_1 A 1 ​ lectin ( Dolichos biflorus ).

Perform adsorption and elution studies if weak subgroups are suspected.

Group III Discrepancies (Protein Abnormalities and Rouleaux Formation)

Pathophysiology : Hyperproteinemia causes erythrocyte stacking ("rouleaux"), mimicking macroscopic and microscopic agglutination in both forward and reverse grouping.

Common Etiologies :

Monoclonal gammopathies: Multiple Myeloma and Waldenström's Macroglobulinemia .

Elevated acute-phase reactants (elevated fibrinogen) in severe sepsis or inflammation.

Infusion of high-molecular-weight plasma expanders: Dextran or hydroxyethyl starch (HES) .

Incompletely clotted serum containing residual fibrin strands.

Microscopic Appearance : Erythrocytes arrange in cylindrical columns resembling "stacks of coins."

Systematic Resolution :

Forward grouping: Wash patient red blood cells 3 to 4 times with isotonic saline; rouleaux on forward typing is abolished because washing removes paraproteins.

Reverse grouping: Perform the Saline Replacement Technique :

Centrifuge the serum-cell suspension showing apparent agglutination.

Carefully remove the serum supernatant with a fine pipet without disturbing the cell button.

Replace the removed serum with an equal volume (2 drops) of 0.9 % 0.9\% 0.9% physiological saline .

Gently resuspend the cell button and inspect for agglutination.

Interpretation : True antigen-antibody agglutination persists following saline replacement; pseudoagglutination due to rouleaux completely disperses into a smooth, unagglutinated suspension.

Group IV Discrepancies (Miscellaneous and Polyagglutination)

Pathophysiology : Cold-reactive antibodies, unwashed cell contaminants, or unexpected membrane modifications reacting at room temperature.

Common Etiologies :

Potent Cold Autoantibodies : High-titer auto-anti-I or auto-anti-H agglutinates all reagent cells ( A 1 A_1 A 1 ​ , B, and autologous control) at room temperature.

Cold Alloantibodies : Clinically benign alloantibodies such as anti-M , anti- P 1 P_1 P 1 ​ , or anti- L e a Le^a L e a present in patient serum reacting with corresponding antigens present on commercial A 1 A_1 A 1 ​ or B reagent red cells.

Wharton's Jelly Contamination : Umbilical cord blood samples collected from the placenta are frequently contaminated with viscous hyaluronic acid-rich Wharton's jelly, causing non-specific agglutination in all forward typing tubes.

Polyagglutinable Red Blood Cells (T-activation) : Bacterial neuraminidase cleave terminal sialic acid residues, exposing hidden cryptantigens ( Thomsen-Friedenreich / T antigen ). Because all adult human sera contain naturally occurring anti-T, these T-activated cells are agglutinated by virtually all human reagents.

Systematic Resolution :

For Cold Autoantibodies : Perform the 37 ∘ C 37^\circ\text{C} 3 7 ∘ C Prewarming Technique : Prewarm patient serum and reagent red cells separately to 37 ∘ C 37^\circ\text{C} 3 7 ∘ C for 10 minutes, mix while maintaining 37 ∘ C 37^\circ\text{C} 3 7 ∘ C , centrifuge at 37 ∘ C 37^\circ\text{C} 3 7 ∘ C , and read immediately. Alternatively, perform cold autologous adsorption (adsorb serum with patient's own enzyme-treated cells at 4 ∘ C 4^\circ\text{C} 4 ∘ C to remove auto-anti-I).

For Cold Alloantibodies : Perform an unexpected antibody screen; if anti-M is identified, repeat reverse typing using A 1 A_1 A 1 ​ and B reagent cells documented to be antigen-negative (e.g., M-negative A 1 A_1 A 1 ​ cells).

For Wharton's Jelly : Wash cord blood erythrocytes 6 to 8 times with warm ( 37 ∘ C 37^\circ\text{C} 3 7 ∘ C ) physiological saline before forward testing; obtain a fresh non-cord heelstick sample if contamination persists.

6. ABO Discrepancy Classification and Troubleshooting Reference Table

Discrepancy Group Primary Problem Frequent Etiologies Typical Serologic Pattern Definitive Resolution Protocol

Group I Missing or weak reverse antibodies • Age <6 months (neonate); • Advanced age (>70 yr); • Hypogammaglobulinemia; • Stem cell transplant Forward: Clear type; Reverse: Unexpected negative reactions ( 0 0 0 ) in A 1 A_1 A 1 ​ or B tubes Incubate serum with cells at room temperature ( 20 – 24 ∘ C 20\text{--}24^\circ\text{C} 20 – 2 4 ∘ C ) or 4 ∘ C 4^\circ\text{C} 4 ∘ C for 15–30 min; run autocontrol and O cell control concurrently.

Group II Missing or weak forward antigens • A or B subgroups ( A 3 , A x A_3, A_x A 3 ​ , A x ​ ); • Leukemia / MDS; • Soluble substances; • Acquired B phenomenon Forward: Unexpected negative or weak ( 0 to 1 + 0\text{ to }1+ 0 to 1 + ); Reverse: Expected isohemagglutinins intact Wash cells; test with anti-A,B and anti- A 1 A_1 A 1 ​ lectin; for acquired B, test with acidified anti-B (pH 6.0) and autologous serum.

Group III Protein abnormalities / Rouleaux • Multiple Myeloma; • Waldenström's macroglobulinemia; • Fibrinogen / acute phase; • Dextran / HES infusions Forward: False positive ( 2 + 2+ 2 + ); Reverse: False positive ( 2 + 2+ 2 + ) across all reagent cells Wash forward cells 3–4 times with saline; perform Saline Replacement Technique on reverse grouping tubes (rouleaux clears, true agglutination remains).

Group IV Miscellaneous / Cold antibodies / Contamination • Cold auto-anti-I; • Cold allo (anti-M, anti- P 1 P_1 P 1 ​ ); • Wharton's jelly (cord); • Subgroup with anti- A 1 A_1 A 1 ​ Discrepant extra reactions in forward or reverse tubes; autocontrol often positive Perform 37 ∘ C 37^\circ\text{C} 3 7 ∘ C prewarming technique or cold autoadsorption; wash cord cells 6–8 times; use antigen-negative reverse grouping cells; test with Dolichos biflorus .